{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:39:23Z","timestamp":1792809563670,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP24H02663"],"award-info":[{"award-number":["JP24H02663"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Augmented renal clearance (ARC) and febrile neutropenia (FN) increase drug clearance primarily through glomerular filtration. In this study, we evaluated the influence of ARC and FN on dose-normalized trough concentration (C\/D) and\/or clearance of teicoplanin (TEIC) by comparing C\/D between patients with ARC and non-ARC, and C\/D and clearance between patients with FN and non-FN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective, single-center, observational cohort study enrolled 309 patients who received intravenous injections of TEIC between July 2016 and September 2021. Of the 94 patients who met the selection criteria, 25 satisfied the ARC definition, and 31 satisfied the FN definition. Using the Chronic Kidney Disease Epidemiology Collaboration formula, ARC was defined as an estimated glomerular filtration rate of 96.5 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> or higher. FN was defined as an axillary temperature 37.5\u00b0C or higher and neutrophil count of less than 500\/\u03bcL. TEIC clearance was estimated using a population pharmacokinetic model for adult Japanese patients with Bayesian estimation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Compared with the non-ARC group (n = 69), the ARC group (n = 25) had a significantly lower first trough concentration (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.014) and lower C\/D (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.009). By contrast, the FN (n = 31) and non-FN (n = 63) groups did not differ significantly in the first trough concentration, C\/D, or clearance (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.294, 0.945, and 0.337, respectively). Forced-entry multiple regression analysis identified ARC as the only independent factor associated with C\/D (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A higher TEIC loading dose may be required for patients with ARC, regardless of the presence or absence of FN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001320","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T12:55:38Z","timestamp":1743339338000},"page":"385-392","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Augmented Renal Clearance and Febrile Neutropenia on Initial Trough Level and Clearance of Teicoplanin"],"prefix":"10.1097","volume":"47","author":[{"given":"Nozomi","family":"Kondo","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7971","authenticated-orcid":false,"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Tsushita","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Hospital Infection Control Center, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Hospital Infection Control Center, Oita University Hospital, Yufu, Oita, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcrc.2021.08.004","article-title":"Augmented renal clearance in critically ill COVID-19 patients: forewarned is forearmed","volume":"66","author":"Dhaese","year":"2021","journal-title":"J Crit Care"},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"106299","DOI":"10.1016\/j.ijantimicag.2021.106299","article-title":"Pharmacokinetics and pharmacodynamics of ceftolozane\/tazobactam in critically ill patients with augmented renal clearance","volume":"57","author":"Nicolau","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrneph.2011.92","article-title":"Implications of augmented renal clearance in critically ill patients","volume":"7","author":"Udy","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"R6-20250509","first-page":"162","article-title":"Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU","volume":"75","author":"Avedissian","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","article-title":"Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial","volume":"49","author":"Udy","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/0885066618809688","article-title":"Prevalence and risk factors for augmented renal clearance in a population of critically ill patients","volume":"35","author":"Baptista","year":"2020","journal-title":"J Intensive Care Med"},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40560-019-0408-y","article-title":"Enhanced renal clearance and impact on vancomycin pharmacokinetic parameters in patients with hemorrhagic stroke","volume":"7","author":"Morbitzer","year":"2019","journal-title":"J Intensive Care"},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12883-020-01771-8","article-title":"Salt wasting syndrome in brain trauma patients: a pathophysiologic approach using sodium balance and urinary biochemical analysis","volume":"20","author":"Lannou","year":"2020","journal-title":"BMC Neurol"},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jcpt.13193","article-title":"A simple scoring method to predict augmented renal clearance in haematologic malignancies","volume":"45","author":"Saito","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","article-title":"Febrile neutropenia in hematologic malignancies","volume":"8","author":"Keng","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","article-title":"Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"96","author":"Heinz","year":"2017","journal-title":"Ann Hematol"},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199018030-00002","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"18","author":"Rowland","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"R15-20250509","first-page":"CD007022","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"106408","DOI":"10.1016\/j.ijantimicag.2021.106408","article-title":"Population pharmacokinetics of continuous infusion of piperacillin\/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000346","article-title":"Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R18-20250509","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/FTD.0000000000000978","article-title":"Association of vancomycin trough concentration and clearance with febrile neutropenia in pediatric patients","volume":"44","author":"Amano","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R19-20250509","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000000906","article-title":"Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies","volume":"43","author":"Sako","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R20-20250509","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/jcpt.13700","article-title":"Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance","volume":"47","author":"Hu","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R21-20250509","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/phar.2743","article-title":"Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with and without augmented renal clearance: a multicenter cohort","volume":"43","author":"Cucci","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R22-20250509","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s13054-020-03057-4","article-title":"Can augmented renal clearance be detected using estimators of glomerular filtration rate?","volume":"24","author":"Gijsen","year":"2020","journal-title":"Crit Care"},{"key":"R23-20250509","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R24-20250509","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R25-20250509","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"R26-20250509","first-page":"1","article-title":"Population pharmacokinetics of teicoplanin in adult patients","volume":"54","author":"Nakayama","year":"2006","journal-title":"Jpn J Chemother"},{"key":"R27-20250509","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1248\/bpb1978.8.246","article-title":"A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers","volume":"8","author":"Yamaoka","year":"1985","journal-title":"J Pharmacobio Dyn"},{"key":"R28-20250509","doi-asserted-by":"crossref","first-page":"1045895","DOI":"10.3389\/fphar.2022.1045895","article-title":"Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients","volume":"13","author":"Fu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R29-20250509","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:33Z","timestamp":1746792033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001320","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2024-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}